DK1833840T3 - Micromirs - Google Patents
MicromirsInfo
- Publication number
- DK1833840T3 DK1833840T3 DK05800760.0T DK05800760T DK1833840T3 DK 1833840 T3 DK1833840 T3 DK 1833840T3 DK 05800760 T DK05800760 T DK 05800760T DK 1833840 T3 DK1833840 T3 DK 1833840T3
- Authority
- DK
- Denmark
- Prior art keywords
- lna
- deoxynucleotide
- designates
- lna nucleotide
- subscript
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62656304P | 2004-11-09 | 2004-11-09 | |
US64718605P | 2005-01-25 | 2005-01-25 | |
US69972105P | 2005-07-15 | 2005-07-15 | |
US72462105P | 2005-10-07 | 2005-10-07 | |
PCT/DK2005/000721 WO2006050734A2 (en) | 2004-11-09 | 2005-11-09 | Potent lna oligonucleotides for the inhibition of hif-1a expression |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1833840T3 true DK1833840T3 (da) | 2010-10-18 |
Family
ID=36177326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05800760.0T DK1833840T3 (da) | 2004-11-09 | 2005-11-09 | Micromirs |
Country Status (16)
Country | Link |
---|---|
US (3) | US7589190B2 (da) |
EP (1) | EP1833840B9 (da) |
JP (3) | JP4825807B2 (da) |
KR (1) | KR101176245B1 (da) |
AT (1) | ATE476441T1 (da) |
AU (1) | AU2005304112B2 (da) |
BR (1) | BRPI0515726A8 (da) |
CA (1) | CA2587173C (da) |
DE (1) | DE602005022768D1 (da) |
DK (1) | DK1833840T3 (da) |
EA (1) | EA014097B1 (da) |
IL (1) | IL183054A0 (da) |
MX (1) | MX2007005558A (da) |
NO (1) | NO341878B1 (da) |
NZ (1) | NZ555644A (da) |
WO (1) | WO2006050734A2 (da) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2284269T3 (da) | 2002-11-18 | 2017-10-23 | Roche Innovation Ct Copenhagen As | Antisense-design |
US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
DK2141234T3 (da) * | 2003-03-21 | 2016-06-20 | Roche Innovation Ct Copenhagen As | Korte interfererende RNA (siRNA) analoger |
EP1713912B1 (en) * | 2004-01-30 | 2013-09-18 | Santaris Pharma A/S | Modified short interfering rna (modified sirna) |
US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
EP1833840B9 (en) * | 2004-11-09 | 2010-11-10 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a |
CN101437933B (zh) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | 作为药物靶标的天然反义和非编码的rna转录物 |
DK1984382T3 (da) * | 2006-01-27 | 2012-09-03 | Santaris Pharma As | LNA modificerede fosforthiolerede oligonukleotider |
US8329888B2 (en) * | 2006-03-23 | 2012-12-11 | Santaris Pharma A/S | Small internally segmented interfering RNA |
US20090326042A1 (en) | 2006-05-05 | 2009-12-31 | Isis Pharmaceuticals, Inc | Compounds and methods for modulating expression of crp |
AU2007296055A1 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
EP2149605B1 (en) | 2007-03-22 | 2013-07-03 | Santaris Pharma A/S | Short RNA antagonist compounds for the modulation of target mRNA |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
WO2009020119A1 (ja) * | 2007-08-06 | 2009-02-12 | Senju Pharmaceutical Co., Ltd. | HIF-1αおよびHIF-2α発現阻害物質含有医薬 |
EP2548962B1 (en) | 2007-09-19 | 2016-01-13 | Applied Biosystems, LLC | Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof |
WO2009043759A2 (en) * | 2007-10-04 | 2009-04-09 | Santaris Pharma A/S | Short rna antagonist compounds for the modulation of hif1alpha |
KR101770435B1 (ko) | 2008-10-03 | 2017-09-05 | 큐알엔에이, 인크. | 자연 안티센스 전사체가 아포리포단백질-a1로 억제에 의해 아포리포단백-a1 관련된 질환의 치료 |
WO2010065671A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
ES2629630T3 (es) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO |
ES2762610T3 (es) | 2009-02-12 | 2020-05-25 | Curna Inc | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF |
MX2011009751A (es) | 2009-03-16 | 2011-09-29 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2. |
WO2010107740A2 (en) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
JP6250930B2 (ja) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療 |
CN102459596B (zh) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
KR101742334B1 (ko) | 2009-05-08 | 2017-06-01 | 큐알엔에이, 인크. | Dmd 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료 |
CN102575251B (zh) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病 |
KR101703695B1 (ko) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | 전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료 |
CN103221541B (zh) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | 通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病 |
KR101702689B1 (ko) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료 |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
CA2768947C (en) | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US9234199B2 (en) | 2009-08-05 | 2016-01-12 | Curna, Inc. | Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS) |
EP2464731B1 (en) | 2009-08-11 | 2016-10-05 | CuRNA, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
WO2011022606A2 (en) | 2009-08-21 | 2011-02-24 | Curna, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
CN102482671B (zh) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病 |
EP2480669B1 (en) | 2009-09-25 | 2017-11-08 | CuRNA, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
AR078770A1 (es) | 2009-10-27 | 2011-11-30 | Elara Pharmaceuticals Gmbh | Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas. |
ES2661813T3 (es) | 2009-12-16 | 2018-04-04 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1 |
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
CA2782373C (en) | 2009-12-23 | 2019-03-26 | Opko Curna, Llc | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
ES2585829T3 (es) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63 |
WO2011090740A2 (en) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
KR101878501B1 (ko) | 2010-01-04 | 2018-08-07 | 큐알엔에이, 인크. | 인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료 |
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
DK2524039T3 (da) | 2010-01-11 | 2018-03-12 | Curna Inc | Behandling af kønshormonbindende globulin- (shbg) relaterede sygdomme ved hæmning af naturligt antisense-transskript mod shbg |
CN102782135A (zh) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病 |
CN102844435B (zh) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病 |
ES2657969T3 (es) | 2010-04-02 | 2018-03-07 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3 |
RU2610661C2 (ru) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21 |
CN107988228B (zh) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病 |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
CA2799596C (en) | 2010-05-26 | 2020-09-22 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
RU2585491C2 (ru) * | 2010-06-04 | 2016-05-27 | Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем | Регуляция метаболизма с помощью mir-378 |
KR102008708B1 (ko) | 2010-06-23 | 2019-08-08 | 큐알엔에이, 인크. | 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료 |
CN103068982B (zh) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病 |
EP2625274B1 (en) | 2010-10-06 | 2017-07-19 | CuRNA, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
CN103459599B (zh) | 2010-11-23 | 2017-06-16 | 库尔纳公司 | 通过抑制nanog的天然反义转录物而治疗nanog相关疾病 |
WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
US10017764B2 (en) | 2011-02-08 | 2018-07-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
JP6188686B2 (ja) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー,インコーポレイテッド | フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療 |
CA2847811C (en) | 2011-09-06 | 2019-10-22 | Curna, Inc. | Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules |
US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US20150291958A1 (en) * | 2012-11-15 | 2015-10-15 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
CN105451778B (zh) * | 2013-06-04 | 2021-08-03 | 哈佛大学校长及研究员协会 | Rna-导向的转录调控 |
JP7012033B2 (ja) | 2016-06-17 | 2022-02-10 | エフ.ホフマン-ラ ロシュ アーゲー | インビトロ腎毒性スクリーニングアッセイ |
EP3472348B1 (en) * | 2016-06-17 | 2022-06-29 | F. Hoffmann-La Roche AG | In vitro nephrotoxicity screening assay |
WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5278324A (en) | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
US5227400A (en) | 1991-09-23 | 1993-07-13 | Florida State University | Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them |
US5250683A (en) | 1991-09-23 | 1993-10-05 | Florida State University | Certain substituted taxanes and pharmaceutical compositions containing them |
US5272171A (en) | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
FR2688518B1 (fr) | 1992-03-13 | 1994-05-06 | Rhone Poulenc Rorer Sa | Procede de preparation de derives du taxane. |
US5248796A (en) | 1992-06-18 | 1993-09-28 | Bristol-Myers Squibb Company | Taxol derivatives |
US5254580A (en) | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5882914A (en) | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
US6770748B2 (en) * | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
US5994076A (en) * | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
IL135000A0 (en) | 1997-09-12 | 2001-05-20 | Exiqon As | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
WO1999048916A2 (en) | 1998-03-27 | 1999-09-30 | The Board Of Trustees Of The Leland Stanford Jr. University | Hypoxia-inducible human genes, proteins, and uses thereof |
US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
EP1161439B1 (en) | 1999-03-18 | 2010-04-21 | Exiqon A/S | Xylo-lna analogues |
ATE332909T1 (de) | 1999-03-24 | 2006-08-15 | Exiqon As | Verbesserte synthese für 2.2.1.öbicyclo- nukleoside |
AU4471700A (en) | 1999-04-26 | 2000-11-10 | University Of North Carolina At Chapel Hill, The | Antisense human fucosyltransferase sequences and methods of use thereof |
KR100782896B1 (ko) | 1999-05-04 | 2007-12-06 | 엑시콘 에이/에스 | L-리보-lna 유사체 |
WO2000076497A1 (en) | 1999-06-14 | 2000-12-21 | Cancer Research Ventures Limited | Cancer therapy |
JP2003502383A (ja) | 1999-06-21 | 2003-01-21 | マードック チルドレンズ リサーチ インスティチュート | 医学的障害の予防及び/又は治療のための方法 |
US6168950B1 (en) * | 1999-07-23 | 2001-01-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEKK1 expression |
IL148916A0 (en) | 1999-10-04 | 2002-09-12 | Exiqon As | Design of high affinity rnase h recruiting oligonucleotide |
US6706505B1 (en) * | 2000-03-08 | 2004-03-16 | Amgen Inc | Human E3α ubiquitin ligase family |
NZ524894A (en) * | 2000-09-02 | 2005-03-24 | Gruenenthal Chemie | Antisense oligonucleotides against VR1 |
EP1334109B1 (en) | 2000-10-04 | 2006-05-10 | Santaris Pharma A/S | Improved synthesis of purine locked nucleic acid analogues |
US7105656B2 (en) | 2000-10-26 | 2006-09-12 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating hematologic malignancies and multiple drug resistance |
WO2002094250A2 (en) | 2001-05-18 | 2002-11-28 | Cureon A/S | Therapeutic uses of lna-modified oligonucleotides in infectious diseases |
DE60232443D1 (de) | 2001-06-05 | 2009-07-09 | Masahiro Hiraoka | Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna |
US7153954B2 (en) * | 2001-07-12 | 2006-12-26 | Santaris Pharma A/S | Method for preparation of LNA phosphoramidites |
DK1409497T3 (da) | 2001-07-12 | 2005-05-30 | Santaris Pharma As | Fremgangsmåde til fremstilling af LNA-phosphoramiditer |
DK2264172T3 (da) * | 2002-04-05 | 2017-11-27 | Roche Innovation Ct Copenhagen As | Oligomerforbindelser til modulering af HIF-1á-ekspression |
DK1501848T3 (da) | 2002-05-08 | 2007-10-22 | Santaris Pharma As | Syntese af låst nukleinsyrederivater |
JP5449639B2 (ja) * | 2002-11-01 | 2014-03-19 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | HIF−1アルファのsiRNA阻害に関する組成物及び方法 |
DK2284269T3 (da) | 2002-11-18 | 2017-10-23 | Roche Innovation Ct Copenhagen As | Antisense-design |
US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
AU2004209599A1 (en) | 2003-02-10 | 2004-08-19 | Santaris Pharma A/S | Oligomeric compounds for the modulation of ras expression |
DE602004022020D1 (de) | 2003-02-10 | 2009-08-27 | Santaris Pharma As | Oligomere verbindungen zur modulation der expression von survivin |
EP1833840B9 (en) * | 2004-11-09 | 2010-11-10 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a |
-
2005
- 2005-11-09 EP EP05800760A patent/EP1833840B9/en active Active
- 2005-11-09 AU AU2005304112A patent/AU2005304112B2/en not_active Ceased
- 2005-11-09 US US11/271,686 patent/US7589190B2/en not_active Expired - Fee Related
- 2005-11-09 MX MX2007005558A patent/MX2007005558A/es unknown
- 2005-11-09 CA CA2587173A patent/CA2587173C/en not_active Expired - Fee Related
- 2005-11-09 NZ NZ555644A patent/NZ555644A/en not_active IP Right Cessation
- 2005-11-09 BR BRPI0515726A patent/BRPI0515726A8/pt not_active Application Discontinuation
- 2005-11-09 DE DE602005022768T patent/DE602005022768D1/de active Active
- 2005-11-09 DK DK05800760.0T patent/DK1833840T3/da active
- 2005-11-09 AT AT05800760T patent/ATE476441T1/de not_active IP Right Cessation
- 2005-11-09 KR KR1020077012303A patent/KR101176245B1/ko active IP Right Grant
- 2005-11-09 JP JP2007539463A patent/JP4825807B2/ja not_active Expired - Fee Related
- 2005-11-09 WO PCT/DK2005/000721 patent/WO2006050734A2/en active Application Filing
- 2005-11-09 EA EA200701033A patent/EA014097B1/ru not_active IP Right Cessation
-
2007
- 2007-05-08 IL IL183054A patent/IL183054A0/en not_active IP Right Cessation
- 2007-06-08 NO NO20072933A patent/NO341878B1/no not_active IP Right Cessation
-
2009
- 2009-06-03 US US12/477,261 patent/US7939507B2/en active Active
-
2011
- 2011-04-04 US US13/079,525 patent/US8410071B2/en not_active Expired - Fee Related
- 2011-08-15 JP JP2011177731A patent/JP2011229540A/ja not_active Withdrawn
-
2014
- 2014-02-21 JP JP2014031436A patent/JP2014098027A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US7939507B2 (en) | 2011-05-10 |
ATE476441T1 (de) | 2010-08-15 |
DE602005022768D1 (de) | 2010-09-16 |
JP2014098027A (ja) | 2014-05-29 |
KR101176245B1 (ko) | 2012-08-22 |
AU2005304112B2 (en) | 2009-06-04 |
KR20070094891A (ko) | 2007-09-27 |
EP1833840B1 (en) | 2010-08-04 |
NZ555644A (en) | 2009-04-30 |
CA2587173A1 (en) | 2006-05-18 |
US8410071B2 (en) | 2013-04-02 |
EA200701033A1 (ru) | 2007-12-28 |
MX2007005558A (es) | 2008-01-31 |
CA2587173C (en) | 2016-09-06 |
US7589190B2 (en) | 2009-09-15 |
EP1833840A2 (en) | 2007-09-19 |
US20090286859A1 (en) | 2009-11-19 |
US20110183931A1 (en) | 2011-07-28 |
EP1833840B9 (en) | 2010-11-10 |
WO2006050734A3 (en) | 2006-08-03 |
IL183054A0 (en) | 2007-09-20 |
BRPI0515726A8 (pt) | 2017-09-12 |
AU2005304112A1 (en) | 2006-05-18 |
EA014097B1 (ru) | 2010-08-30 |
NO20072933L (no) | 2007-06-08 |
US20060252721A1 (en) | 2006-11-09 |
JP4825807B2 (ja) | 2011-11-30 |
JP2011229540A (ja) | 2011-11-17 |
JP2008518608A (ja) | 2008-06-05 |
WO2006050734A2 (en) | 2006-05-18 |
BRPI0515726A (pt) | 2008-08-05 |
NO341878B1 (no) | 2018-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1833840T3 (da) | Micromirs | |
IL196798A0 (en) | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS | |
ES2530671T3 (es) | Silenciamiento de genes | |
IL300119A (en) | Oligonucleotides to induce paternal UBE3A expression | |
DK1877070T3 (da) | Terapeutisk anvendelse af TGF-beta2 antisense-oligonucleotider | |
NZ630921A (en) | Compounds and methods for enhanced cellular uptake | |
MX2021012126A (es) | Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central. | |
DK1706489T3 (da) | Oligomer forbindelser for modulationen af BCL-2 | |
WO2005089287A3 (en) | Methods and compositions for the specific inhibition of gene expression by double-stranded rna | |
WO2009017803A8 (en) | Antisense microrna and uses therefor | |
ATE477337T1 (de) | Zusammensetzungen und verfahren zur sirna-hemmung von icam-1 | |
ATE467688T1 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion | |
WO2008132234A4 (en) | Rna antagonist compounds for the modulation of beta-catenin | |
NZ717921A (en) | Microrna compounds and methods for modulating mir-21 activity | |
MXPA05011221A (es) | Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi. | |
RU2015155332A (ru) | Олигонуклеотидные модуляторы в-клеточной cll/лимфомы 11а (bcl11а) и их применение | |
PE20212248A1 (es) | Molecula oligomerica de acido nucleico y uso de esta | |
HK1113318A1 (en) | Oligonucleotide and compositions comprising the same for treating b cell neoplasm | |
UA93188C2 (ru) | Эффективные олигонуклеотиды lna для ингибирования экспрессии hif-1a | |
Yamada et al. | Remarkable stabilization of antiparallel DNA triplexes by strong stacking effects of consecutively modified nucleobases containing thiocarbonyl groups | |
Langkjær et al. | Watson–Crick hydrogen bonding of unlocked nucleic acids | |
Fujimoto et al. | Short oligonucleotide prodrug having 5-fluoro and 5-iodouracil inhibits the proliferation of cancer cells in a photo-responsive manner | |
WO2023015153A3 (en) | ANTISENSE OLIGONUCLEOTIDE TARGETING APOE ε4 AND USES THEREOF | |
Torrence et al. | Evaluation of synthetic oligonucleotides as inhibitors of West Nile virus replication | |
Srivastava et al. | Emerging role of microRNA in drought stress tolerance in the biofuel, bioenergy crop sugarcane |